all the information, none of the junk | biotech • healthcare • life sciences

Lotus Pioneers New Treatment for Rare and Disfiguring Disorder, Raises $26 Million From Third Rock

Today marks the debut of Lotus Tissue Repair, a Cambridge, MA-based company that’s developing a treatment for a rare, genetic disease called dystrophic epidermolysis bullosa (DEB). The disease may not be well known, but the folks behind the startup certainly are. Lotus has closed a $26 million Series A financing round led by Boston-based Third Rock Ventures. Co-founders include Philip Reilly, a Third Rock partner and a clinical geneticist by training, and Mark de Souza, a veteran of Cambridge biotech Dyax (NASDAQ: DYAX).

DEB only affects about 300 people in the U.S., but it ends up being a death sentence for many of those patients. The disease, which emerges during childhood, is caused by a deficiency or malfunction of a protein called collagen type VII. DEB causes painful skin blisters that can result in fingers and toes getting fused together. Sometimes the blisters erupt in the esophagus, making it difficult for patients to eat. And the disease puts its victims at high risk of developing squamous cell carcinoma—a deadly skin cancer. “These children suffer terribly, then they develop a fatal cancer in their adult years,” says Reilly, who specializes in finding opportunities in rare diseases for Third Rock. “And there is no effective therapy.”

Lotus was co-founded by University of Southern California (USC) dermatology professors Mei Chen and David Woodley, who licensed their technology to the startup. Chen and Woodley developed a genetically engineered form of collagen type VII called rC7, which they believe could be given to DEB patients to keep the disease in check. The researchers have performed a number of animal studies showing that the protein replacement treatment specifically zeroes in on wounded skin, healing it in a potent and long-lasting manner.

Chen and Woodly recently received grant money to start the first human trials, which will begin at USC shortly, de Souza says. The company has not yet determined the timeline for the complete clinical-trial program, but with the new source of cash, he says, “We’ll be able to move forward quickly.”

DEB is so rare that it’s considered an “ultra-orphan” disease, de Souza says. But USC’s early research indicates that rC7 might also work in other skin disorders that are much more common, such as diabetic foot ulcers—a key consideration in determining the technology’s promise as a commercial product. “The pre-clinical evidence shows that collagen VII plays a role in accelerating healing, so we think there’s a huge upside in treating other types of chronic wounds,” says de Souza, who is … Next Page »

Single PageCurrently on Page: 1 2